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Early Breast Cancer
Therapy and Cardiovascular Injury
The paper by Jones et al. (1) provides an excellent review of the
cardiovascular toxicity incurred during treatment for breast cancer.
Late cardiotoxicity from anthracyclines has been recognized in
survivors of childhood cancer (2) and is more recently being
addressed in survivors of breast cancer. The section by Jones et al.
on “Prevention and/or Treatment” contains many important ap-
proaches. It is surprising, however, that dexrazoxane is not men-
tioned.
Dexrazoxane was shown in the 1980s to afford protection from
cardiotoxicity in women with breast cancer (3). Its use was limited
after a multicenter trial, in advanced breast cancer, reported by
Swain et al, confirmed cardioprotection, but showed, in 1 of the 5
study arms, a better tumor response in the control patients
compared with those treated with dexrazoxane (4). As a result, the
indication for breast cancer was restricted to patients who had
already received 300 mg/m2 doxorubicin, pending further trials.
Further trials were subsequently conducted in patients with
pediatric cancers, including Ewing’s sarcoma, osteosarcoma,
Hodgkin’s lymphoma, and leukemia. These trials demonstrated
cardioprotection, with no decrease in anticancer efficacy, when
dexrazoxane was added to chemotherapeutic protocols. It is there-
for used with initial therapy in pediatric patients. It has allowed
treatment with cumulative doxorubicin doses up to 600 mg/m2,
without cardiac failure (5). It is, therefore, time for the use of
dexrazoxane to be investigated again in women with breast cancer
during initial treatment, to provide them with protection against
future cardiotoxicity.
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Reply
We thank Dr. Steinherz for the important comments regarding
the use of dexrazoxane as a prevention/treatment strategy for
anthracycline-induced cardiotoxicity in cancer patients. The pri-
mary focus of our paper was to examine the risk of and preventive/
treatment strategies for long-term global cardiovascular disease
(CVD) as opposed to the specific entity of anthracycline-induced
cardiotoxicity (1). We feel that this is important to stress because
the risk of late-occurring CVD in women diagnosed with early
breast cancer likely far exceeds the risk of symptomatic
anthracycline-induced cardiac dysfunction during therapy. Clearly,
prevention/treatment of cardiac toxicity is of major clinical impor-
tance in breast and several other cancer populations, as highlighted
by Dr. Steinherz. Further, acute and delayed cardiac toxicity likely
contribute to the risk of late-occurring CVD as a component of the
“multiple-hit” hypothesis as described in our paper (1). To this
end, we agree with Dr. Steinherz that clinical trials of dexrazoxane
are required in women receiving chemotherapy in the early stages
of disease. However, we wanted to highlight strategies for the
treatment of risk factors for the global prevention of CVD in
women (e.g., lifestyle modification in conjunction with pharma-
cotherapy) which has not, in our opinion, received adequate
attention in oncology.
Finally, to our knowledge, dexrazoxane has only been investi-
gated and approved by the Food and Drug Administration among
breast cancer patients in the metastatic (advanced) setting who
have received a cumulative dose of 300 mg/m2 (2). Given that the
focus of our paper was cardiovascular injury among women
diagnosed with early-stage disease, we felt inclusion of this
approach was not warranted.
*Lee W. Jones, PhD
Mark J. Haykowsky, PhD
Pamela S. Douglas, MD
John R. Mackey, MD
*Box 3624
Duke University Medical Center
Durham, North Carolina 27710
E-mail: lee.w.jones@duke.edu
doi:10.1016/j.jacc.2007.12.016
REFERENCES
1. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early
breast cancer therapy and cardiovascular injury. J Am Coll Cardiol
2007;50:1435–41.
2. Hensley ML, Schuchter LM, Lindley C, et al. American Society of
Clinical Oncology clinical practice guidelines for the use of chemother-
apy and radiotherapy protectants. J Clin Oncol 1999;17:3333–55.
1235JACC Vol. 51, No. 12, 2008 Correspondence
March 25, 2008:1232–5
